Interview Questions for Ed Kim, City of Hope
Interview with Track Chair: Edward S. Kim, MD, City of Hope Interview with PMWC 2026 Track Chair: Edward S. Kim, MD, City of Hope Responses to interview questions from Tal Behar, Precision Medicine World Conference Edward S. Kim, MD, Vice Physician-in-Chief, City of Hope National Medical Center; System Director, Clinical Trials, City of Hope Track […]
Interview Questions for Dennis J. Slamon, UCLA
Interview with Pioneer Honoree: Dennis J. Slamon, UCLA Interview with Pioneer Honoree: Dennis J. Slamon, UCLA Responses to interview questions from Tal Behar, Precision Medicine World Conference Keynote in Track 3 Day 2: Molecular Diversity of Human Malignacies: Diagnostic and Therapeutic Implications PMWC 2026 Pioneer Honoree Track 3 Day 2 Keynote View the Full PMWC […]
Interview Questions for Dmitry Gabrilovich, AstraZeneca
Dmitry Gabrilovich (AstraZeneca) Responses to interview questions from Tal Behar, Precision Medicine World Conference 1. Trial Design Question: In myeloid-targeting combination trials in solid tumors, what’s the most common trial-design mistake you see (patient selection, timing, endpoints, assays), and what one change would you make first to avoid false “no-signal” outcomes? Answer: The challenges with […]
Interview Questions for Suzanne Topalian, Johns Hopkins
Suzanne Topalian’s (Johns Hopkins) responses to interview questions from Tal Behar, Precision World Medicine Conference 1) The single biomarker you’d actually gate treatment on in 2026 (setting + cutoff) — and why. In my opinion, the single most reliable biomarker for anti-PD-1-based therapy, among three that are currently FDA-approved and many that are still in […]
Interview Questions for Jamez Zou, Stanford
James Zou’s (Stanford) responses to interview questions from Tal Behar, Precision World Medicine ConferenceQ1.When your virtual AI lab started generating and debating its own hypotheses, what was one idea or research direction it proposed that genuinely surprised you, and what did that moment change in how you think about discovery?A1. The virtual lab AI agents […]
Interview Questions for Ron Alfa, NOETIK
Ron Alfa (NOETIK) Responses to interview questions from Tal Behar, Precision Medicine World Conference 1. What unique role does Noetik’s “virtual patient” platform play in reshaping how we approach clinical trials or drug development?The fundamental failure mode in our industry isn’t that we can’t design good molecules; it’s that we test them in models that […]
Interview Questions for Arul Chinnaiyan, University of Michigan
Arul Chinnaiyan’s from University of Michigan and Michigan Medicine responses to interview questions from Tal Behar, Precision World Medicine Conference 1. Breaking the Gene Fusion Paradigm: Your discovery of the TMPRSS2-ERG gene fusion – now recognized as a defining molecular event in prostate cancer – broke new ground by revealing that gene fusions can drive common […]
Interview Questions for Jeff Balser, VUMC
Precision Medicine World Conference Jeff Balser Interview 1. AI / operations VUMC’s strategy is to use AI to scale as a means to grow while better controlling increases in staffing. In what areas are you focusing? Our approach is to focus on specific domains while developing standard platforms and processes to facilitate AI implementation […]
Interview Questions for Joe Petro, Microsoft Dragon
Joe Petro’s responses to interview questions from Tal Behar, Precision World Medicine Conference Q1. What impact is Dragon Copilot having today, and what outcomes are you prioritising for 2026?A1. Dragon Copilot gives clinicians time back and reduces cognitive burden—shifting focus from paperwork to patients.What began with physicians now increasingly supports nurses and radiologists. In 2026, […]
Interview Questions for Daniel De Carvalho
Daniel De Carvalho responses to interview questions from Tal Behar, Precision World Medicine Conference Daniel D. De Carvalho, PhDProfessor, University of Toronto; ALLAN SLAIGHT Senior Scientist, Princess Margaret Cancer Centre/University Health Network; Co-Founder and CSO, Adela Where does methylation add indispensable value in MRD vs mutation‑only approaches (e.g., low‑shedding tumors, tissue‑of‑origin context, earlier relapse […]
